Table 2.
Patient and disease characteristics
| Characteristic | n (%) |
|---|---|
| Patients | 18 (100) |
| Age (y), median, IQR | 70 (62–73) |
| BMI (kg/m2), median, IQR | 25.8 (24.6–28.7) |
| WHO performance status | |
| −0 | 8 (44) |
| −1 | 10 (56) |
| Hormone status | |
| ‐Hormone sensitive | 11 (61) |
| ‐Castration resistant | 7 (39) |
| Metastatic stage at screening | |
| ‐M0 | 5 (28) |
| ‐M1a | 4 (22) |
| ‐M1b | 8 (44) |
| ‐M1c | 1 (6) |
| Gleason score at diagnosis | |
| ‐ ≤7 | 4 (22) |
| ‐ >7 | 14 (77) |
| Type of castration | |
| ‐Bilateral orchidectomy | 1 (6) |
| ‐LHRH analogues | 17 (94) |
| Previous therapy | |
| ‐Radical prostatectomy | 1 (6) |
| ‐Radiotherapy prostate | 3 (16) |
| ‐Hormone therapy | |
| Bicalutamide | 6 (33) |
| Enzalutamide | 2 (11) |
| ‐Radium‐223 | 1 (6) |
| ‐Experimental therapy | 1 (6) |
| Lab results at baseline | Median (IQR) |
| ‐PSA, μg/L | 20 (3–87) |
| ‐Hb, mmol/L | 8 (7–10) |
| ‐LDH, U/L | 196 (178–216) |
| ‐AP, U/L | 103 (70–160) |
| ‐Albumin, g/L | 44 (43–46) |
AP = alkaline phosphatase; BMI = body mass index; Hb = haemoglobin; IQR = interquartile range; LDH = lactate dehydrogenase; LHRH = luteinizing hormone releasing hormone; PSA = prostate specific antigen; WHO = World Health Organization.